LONDON--(BUSINESS WIRE)--The global phosphodiesterase (PDE) inhibitors market is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

The same basic process used by the popular pharmaceutical Viagra may someday help people suffering from a variety of conditions, from allergies to diabetes. Viagra’s success has raised interest in the ...

DUBLIN--(BUSINESS WIRE)--The "Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...

Prostacyclin (PGI2) and phosphodiesterase 5 (PDE5) inhibitors are vasodilators used in the treatment of pulmonary arterial hypertension (PAH). Although these drugs stimulate vascular dilation directly ...

Benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) and erectile dysfunction commonly coexist, and both respond to phosphodiesterase (PDE) 5 inhibitors, suggesting a shared ...

Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference. New insights into the ...

(MENAFN- Market Press Release) July 14, 2025 4:07 am - The Phosphodiesterase-4 (PDE-4) inhibitors market is growing due to increasing prevalence of inflammatory diseases like COPD, psoriasis, and ...

(HealthDay News) — Phosphodiesterase type 5 inhibitor use after radical prostatectomy is associated with increased risk of biochemical recurrence, according to a study published in the February issue ...

The time to onset of action was fastest with IL-17 inhibitors, followed by IL-23, IL-12/23, then PDE-4 and JAK inhibitors for ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...